Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MBIO, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Chimeric Antigen Receptor T-cells | Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1/2 · NCT03277729 | Active not recruiting |
| Fludarabine | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC | Phase 1/2 · NCT04109482 | Terminated |
| Autologous CD123CAR-CD28-CD3zeta-EGFRt-e | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC | Phase 1/2 · NCT04109482 | Terminated |
| Autologous Anti-CD20CAR-CD28-4-1BB-CD3ze | Follicular B-cell Non-Hodgkin's Lymphoma | Phase 1/2 · NCT05360238 | Terminated |
| Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-e | Adult Acute Myeloid Leukemia in Remission | Phase 1 · NCT02159495 | Active not recruiting |
| Autologous CD123CAR-CD28-CD3zeta-EGFRt-e | Adult Acute Myeloid Leukemia in Remission | Phase 1 · NCT02159495 | Active not recruiting |
| Prior MB-102 CAR-T cell investigational | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC | N/A · NCT05645744 | Terminated |
| Prior MB-106 CAR-T cell investigational | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC | N/A · NCT05645744 | Terminated |
Also used in these trials (approved or third-party drugs, not MBIO's own candidates): Cyclophosphamide, Fludarabine Phosphate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MBIO holds $15.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $987,500/quarter from operations, an estimated runway of 46 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBIO files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →